BioCentury
ARTICLE | Company News

Amgen suing Sandoz over Enbrel biosimilar

March 1, 2016 2:10 AM UTC

Amgen Inc. (NASDAQ:AMGN) filed suit against the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) in the U.S. District Court for the District of New Jersey alleging that Sandoz's biosimilar etanercept ( GP2015) infringes five patents covering Amgen's Enbrel etanercept, the reference product.

The complaint also states Sandoz has refused to follow the patent resolution protocol laid out by the Biologics Price Competition and Innovation Act (BPCIA). According to Amgen, Sandoz has failed to "engage in negotiation and exchange of patent lists" as specified by the BPCIA. ...